CN109806241A - A kind of double medicine albumin nano granulars and preparation process - Google Patents
A kind of double medicine albumin nano granulars and preparation process Download PDFInfo
- Publication number
- CN109806241A CN109806241A CN201910158514.2A CN201910158514A CN109806241A CN 109806241 A CN109806241 A CN 109806241A CN 201910158514 A CN201910158514 A CN 201910158514A CN 109806241 A CN109806241 A CN 109806241A
- Authority
- CN
- China
- Prior art keywords
- albumin
- taxol
- resveratrol
- double medicine
- albumin nano
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
A kind of taxol/resveratrol albumin nanoparticle provided by the invention and preparation process, its step are as follows: (1) preparing taxol, resveratrol stock solution；(2) albumin stock solution is prepared；(3) double medicine albumin nano granulars are prepared.Anticarcinogen taxol and bioactive substance resveratrol are administered in combination by the present invention, can improve its antitumous effect while reducing toxic side effect；Double medicine albumin nano granular encapsulation rates prepared by the present invention are up to 99%, and with good stability；Double medicine albumin nano granulars provided by the invention can sequentially discharge, and the quick release of resveratrol is conducive to inhibit the effect of P-gp, avoid the taxol of subsequent release from pumping out from tumour cell, to increase its cytotoxicity to cells of resistant tumors；Double medicine albumin nano granular cell in vitro poison experiments provided by the invention confirm to realize the synergistic antitumor effect of taxol and resveratrol in double medicine nanoparticles with the drug resistance of reversing tumor cell.
Description
Technical field
The invention belongs to biopharmaceutical technology, it is specifically related to nanoparticle and preparation that a kind of albumin contains double medicines
Technique.
Background technique
Cancer is human life is seriously threatened in world wide main dead together with cardiovascular and cerebrovascular disease and contingency
Die one of reason.And most of cancer related mortalities are the resistances due to metastatic tumo(u)r to chemotherapy, so multidrug resistance
(MDR) be considered as treatment of cancer major obstacle.Multidrug resistance causes the chemotherapy of many cancers to fail, including breast cancer,
Oophoroma, lung cancer, gastrointestinal cancer and Malignancy etc..Although repeatedly attempting to overcome MDR, drug resistant cancer is controlled
Treatment is still an important medical problem.
The elementary tactics for treating resistant tumors is drug combination.For a long time, combination therapy is used as several pernicious swollen
The standard first-line therapy of tumor, to improve clinical effectiveness.The combination therapy of anticancer drug has been displayed induction of combined drug effect simultaneously
Prevent the generation of drug resistance.
Delivering a variety of anticancer drugs jointly by nano-carrier is the further method for improving combination therapy effect.Standard connection
The effect for closing treatment is limited to the different pharmacokinetics of drug, the uncoordinated intake so as to cause tumour cell to various drugs
And reduce the effect of its Synergistic anti-cancer.Several drugs can be delivered to identical tumour cell by nano-carrier, to promote them
To the synergistic effect of target cancer cell.Nano-carrier can provide relatively high drug load, this may inhibit cancer cell
Drug flows out mechanism, to enhance the antitumaous effect of drug.Further, since the permeability of secondary enhancing and reservation (EPR) effect
It answers, drug-carrying nanometer particle may be gathered in tumor locus.
Resveratrol (RES) and taxol (PTX) are phytoalexin and clinically widely applied anticarcinogen respectively.It is purple
China fir alcohol is microtubule stabilizing agent, can block normal function and the mitosis of micro-pipe.And resveratrol is verified it with anti-
Cancer, anti-inflammatory, anti-oxidant, anti-aging are hypoglycemic and other effects.In addition, resveratrol also has been proved to possess multidrug resistance
The antiproliferative activity of tumour cell.Resveratrol and taxol are embedded in albumin jointly, and use Anticancer Activity in vitro
MDR is assessed to reverse.It selects albumin as nano-carrier, is because albumin has biodegradable, nontoxic and chemistry is steady
The advantages that qualitative and be widely used in nanosecond medical science.Bovine serum albumin(BSA) (BSA) is the main soluble protein of the circulatory system,
With structure similar with human serum albumins, due to its stability, biocompatibility and low cost are typically used as nanometer load
Body.
Summary of the invention
In view of the deficiencies of the prior art, the present invention provides a kind of double medicine albumin nano granulars, composition includes albumin, dredges
Aqueous pharmaceutical taxol and resveratrol.
Preferably, the albumin is bovine serum albumin(BSA).
Preferably, the molar ratio of albumin and hydrophobic drug is 1:9.
Preferably, double medicine albumin nano granular partial sizes are 100-200nm.
Preferably, the drugloading rate of taxol, resveratrol is between 1-5%.
Preferably, the encapsulation rate of taxol, resveratrol is 99% or more.
Preferably, double medicine albumin nano granulars have reversed the drug resistance of taxol resistance cell.
A kind of double medicine albumin nano granulars, preparation process combine the anti-solvent precipitation method and high pressure homogenization method, specifically include
Following steps:
A. albumin is dissolved in water three times, is sufficiently dissolved；
B. two kinds of hydrophobic drugs are dissolved in organic solvent；
C. the organic solvent of step b is added in the albumin aqueous solution of step a, stirs 10min；
D. the solution vacuum distillation of step c is removed into organic solvent；
E. the solution progress of step d is high-pressure homogeneous, size controlling is obtained in double medicine albumin nanos of 100-200nm
Grain；
The excellent effect that the present invention obtains is:
1. novelty of the present invention proposes the nanoparticle that a kind of albumin contains double medicines.Anticarcinogen and normal tissue are damaged
Hurt small bioactive substance joint co-administered, its antitumous effect can be improved while reducing toxic side effect；
2. double medicine albumin nano granular encapsulation rates prepared by the present invention are up to 99%, and with good stability, 4
It is placed 2 weeks under the conditions of DEG C, significant change does not occur for nanoparticle partial size.And the also stability with higher in DMEM；
3. the ratio that the present invention has screened double medicines in double medicine albumin nano granulars by partial size；
It is discharged 4. sequence may be implemented in double medicine albumin nano granulars provided by the invention, the quick release of resveratrol is advantageous
In the effect for inhibiting P-gp, thus reversing drug resistance.
Detailed description of the invention
The DLS curve of Fig. 1 taxol/resveratrol albumin nanoparticle in water；
Fig. 2 taxol/resveratrol albumin nanoparticle TEM picture；
Fig. 3 taxol/resveratrol albumin nanoparticle XRD spectrum；
Fig. 4 taxol/resveratrol albumin nanoparticle release profiles；
Fig. 5 taxol/resveratrol albumin nanoparticle stability；
Cell inhibitory rate of Fig. 6 albumin nano granular to A549 (A), A549/tax (B), 4T1 (C).
Specific embodiment
Below by specific embodiment, the invention will be further described, to help to better understand in of the invention
Hold, but these specific embodiments are not in any way limit the scope of the present invention.
A kind of preparation process of double medicine albumin nano granulars provided by the invention of embodiment 1, its step are as follows: (1) configuring
Taxol, resveratrol stock solution；(2) BSA stock solution is prepared；(3) double medicine albumin nano granulars are prepared；It is specific as follows:
The albumin stock solution of 7mg/mL is prepared with water three times.Prepare the mixed of the taxol and resveratrol for adding acetone solution
And solution, drug total concentration are 10mg/mL；
Drug mixture is added dropwise in the albumin stock solution being stirred continuously, continues to stir 10min, revolving removes third
Ketone.It is high-pressure homogeneous for several times, obtain double medicine albumin nano granulars.
Test example 1
1.1 instruments and reagent
High performance liquid chromatograph (waters 2489), nano particle size potentiometer (ZetasizerNano ZSP,
Malvarn), pH meter (METTLERTOLEDO FE20).Low speed centrifuge (cence TDZ5-WS, Hunan Hunan instrument Laboratory Instruments
Development corporation, Ltd.).Taxol and resveratrol are mentioned by Dalian U.S. logical sequence Technology Co., Ltd. and TCI Co., Ltd respectively
For bovine serum albumin(BSA) (BSA) is provided by lark prestige.Methanol (HPLC grades) is purchased from Fisher Scientific, and acetone is purchased from state
Chemical reagent Co., Ltd, medicine group, other reagents are that analysis is pure.Experimental water is ultrapure water (Millipore).
The preparation of 1.2 pairs of medicine albumin nano granulars
Double medicine albumin nano granulars are prepared using the sedimentation method combined high pressure homogenization method of anti-solvent.Taxol (2.5mg) and white
Veratryl alcohol (2.5mg) co-dissolve is mixed evenly in the acetone of 0.5mL.BSA (104.9mg) is substantially dissolved in the three of 15mL
Secondary water.Under conditions of being stirred continuously, acetone soln is added dropwise in BSA solution, continues to be protected from light stirring 10min after adding.
Organic solvent-acetone is removed with the method for vacuum distillation.It is high-pressure homogeneous for several times after, obtain taxol/resveratrol albumin and receive
The grain of rice.
1.3 partial sizes, PDI and Zeta potential measurement
At room temperature, using dynamic light scattering (DLS, ZetasizerNano ZSP, Malvarn, UK) measurement taxol/
Partial size, PDI and the current potential of resveratrol albumin nanoparticle, each sample are measured in parallel three times.Parameter: 4mW He-Ne laser
Device, wavelength 633nm, angle of scattering 173o.
1.4 morphological research
The morphological research of taxol/resveratrol albumin nanoparticle using transmission electron microscope (TEM, JEM-2100,
Japan it) is analyzed.
1.5 X-ray powder diffractions (X-ray) analysis
Under room temperature, the freeze-dried powder of taxol raw medicine, resveratrol raw medicine, double medicine nanoparticles and single medicine nanoparticle is used
X-ray powder diffraction instrument carries out crystal form evaluation.Sample measurement parameter: XD-3 type X-ray powder diffraction instrument (copper target, the graphite bent crystal
Monochromator, operating voltage 36kV, electric current 20mA, 2 θ=5 °~50 ° of scanning range, 4 °/min of scanning speed).
The measurement of 1.6 encapsulation rates and drugloading rate
Using ultra-filtration centrifuge tube (AmiconUltra) after ultrafiltration using high performance liquid chromatography (HPLC) measurement taxol/
Non-encapsulated medicament contg in resveratrol albumin nanoparticle, computational envelope rate.
The nanoparticle made is taken and is lyophilized in freeze dryer in right amount.The quality of sample is weighed after freeze-drying.The sample of freeze-drying adds
1mL methanol, vortex 1min or so take supernatant liquor feed liquor phase after centrifugation, obtain drug concentration, calculate drugloading rate.
1.7 stability study
Taxol/resveratrol albumin nanoparticle stability is determined by using DLS measurement partial size.When in order to analyze
Between the stability that relies on, stored 14 days under the conditions of 4 DEG C, measure sample particle diameter respectively at the 0th, 1,3,7,14 day DLS.And it grinds
Stability of the nanoparticle in DMEM is studied carefully.
1.8 release in vitro
It prepares taxol/resveratrol albumin nanoparticle solution (2mL) and is added in bag filter (MWCO, 8-14KDa).
Bag filter immersion 100mL is contained in the 0.1M PBS (pH7.4) of 0.5% (w/v) SDS, at 37 DEG C, rotation speed 100rpm
Isothermal vibration under study release in vitro performance.It is spaced in different times, samples 3ml, and supplement the fresh release of 3mL and be situated between
Matter.The concentration for determining the PTX of release is analyzed by HPLC.
1.9 Anticancer Activity in vitro
A549, A549/TAX and 4T1 cell are for assessing Anticancer Activity in vitro.By A549, A549/TAX and 4T1 cell point
It Jie Zhong (5 × 103Cells/well) in 96 orifice plates, and cell incubator (37 DEG C, 5%CO2) in culture.After 24 hours, use
The culture medium (100 μ L) of nanometer formulation containing various concentration replaces the culture medium in 96 orifice plates, and trains in cell incubator
It supports 48 hours.After culture, MTT solution (20 μ L, 5mg/mL) is added in each hole, and it is small that plate is put into incubator culture 4
When.Then, it discards MTT reagent and DMSO (150 μ L) is added with Rong Xie formazan crystal.Pass through microplate reader (BioTek
Instruments the absorbance at 570nm) is measured.Cell viability is calculated by comparing the absorbance of processing hole and blank well
(%).
2 results and discussion
The preparation of 2.1 pairs of medicine albumin nano granulars
In order to choose taxol and the suitable ratio of resveratrol, it is prepared for pair of taxol and resveratrol different proportion
Medicine albumin nano granular.As shown in Table 1, when the ratio of taxol and resveratrol is 1:1, the grain of double medicine albumin nano granulars
Diameter is the smallest.And the partial size of taxol albumin nano granular and resveratrol albumin nanoparticle and double medicine albumin nanos
The partial size of grain is not much different.Albumin nano granular grain will not be caused on albumin by illustrating that taxol and resveratrol contain jointly
The increase of diameter.It is final to determine that the ratio of taxol and resveratrol is 1:1 in double medicine albumin nano granulars.
The partial size of 1 albumin nano granular of table
2.2 partial sizes, PDI and Zeta potential measurement
Taxol/resveratrol albumin nanoparticle average grain diameter is 168.4 ± 0.7nm.PDI is 0.164 ± 0.029,
From grain-size graph it can be seen that particle diameter distribution is unimodal (see Fig. 1), illustrate that the partial size of nanoparticle is relatively uniform.Taxol/white black false hellebore
The current potential of alcohol albumin nano granular is -32.9 ± 0.62mV.
2.3 morphological research
Pass through tem observation taxol/resveratrol albumin nanoparticle form (Fig. 2).The white egg of taxol/resveratrol
For white nanometer grain appearance in the spherical shape of rule, average grain diameter is about 150nm.The data that observation result is measured with DLS can be tested mutually
Card.
2.4 X-ray powder diffractions (X-ray) analysis
Existence of the PTX and RES in taxol/resveratrol albumin nanoparticle is verified (see figure by XRD spectrum
3).The drug diffraction maximum of PTX and RES respectively appears in the XRD spectrum of raw medicine, and physical mixture can also be observed that slight medicine
Object diffraction maximum, and disappear in nanoparticle.Illustrate PTX and RES is that be present in taxol/resveratrol in the form of unformed white
In protein nano grain.
The measurement of 2.5 encapsulation rates and drugloading rate
Taxol/resveratrol albumin nanoparticle has very high entrapment efficiency.The entrapment efficiency of PTX and RES
Respectively 99.93% and 98.24%.In taxol/resveratrol albumin nanoparticle, the drugloading rate of PTX is 4.00%,
The drugloading rate of RES is 1.54%.The encapsulation rate of double medicine albumin nano granulars is close with the encapsulation rate of single medicine albumin nano granular, says
Understand that the addition of veratryl alcohol has no effect on albumin and contains to taxol.
The encapsulation rate and drugloading rate of 2 albumin nano granular of table
2.6 stability study
The taxol of preparation/resveratrol albumin nanoparticle is placed 2 weeks under the conditions of 4 DEG C, respectively at the 0th, 1,3,
7,14 days measurement sample particle diameters.Taxol/stability of the resveratrol albumin nanoparticle in DMEM is as shown in Figure 4.As a result
It is little to show that taxol/resveratrol albumin nanoparticle places change of size after two weeks, and in DMEM also there is no
The phenomenon that partial size becomes larger suddenly.Illustrate that nanoparticle is placed at 4 DEG C and there is no aggregations in DMEM, there is good stabilization
Property.
2.7 release in vitro
Taxol/resveratrol albumin release profiles are as shown in Figure 5.Taxol and resveratrol show it is unique and
Continuous release mode, wherein resveratrol rate of release is faster than taxol.In resveratrol release nearly 99% in 24 hours, and
In the same period taxol release 55%.By 72 hours, taxol release 81%.This release mode may induce
The synergistic activity of anticancer drug, resveratrol quick release can effectively inhibit the effect of P-gp, prevent taxol thin from tumour
It is pumped out in born of the same parents, thus reverse multidrug resistance.
2.8 Anticancer Activity in vitro
We by comparison albumin nano granular to the cytotoxicities of three kinds of cell lines (A549, A549/TAX and 4T1) come
Study its Anticancer Activity in vitro.Different albumin nano granulars is added in A549, A549/TAX and 4T1 cell, and (taxol is white
Protein nano grain, resveratrol albumin nanoparticle and taxol/resveratrol albumin nanoparticle) it is incubated for 48h, calculate IC50
And CI50(combinatorial index).Fig. 6 is taxol albumin nano granular, resveratrol albumin nanoparticle and taxol/white black false hellebore
Cell inhibitory rate of the alcohol albumin nano granular to A549 (A), A549/Tax (B) and 4T1 (C).Double medicine nanoparticles on tumor cells
Inhibiting rate be apparently higher than single medicine nanoparticle, and it is also very high to the inhibiting rate of A549/TAX, illustrate that double medicine nanoparticles reverse
The drug resistance of tumour cell.Double medicine nanoparticles are less than 1 to the combinatorial index of three kinds of cell lines, illustrate in double medicine nanoparticles
Taxol and resveratrol play synergistic effect over the course for the treatment of.
The IC of table 3 A549, A549/TAX and 4T150
The CI of 4 pairs of medicine nanoparticles of table50
3 conclusions: the application prepares taxol/resveratrol albumin by the sedimentation method combined high pressure homogenization method of anti-solvent and receives
The grain of rice.The average grain diameter of drug-carrying nanometer particle is 168.4nm, and particle diameter distribution is unimodal；Taxol/resveratrol albumin nanoparticle
Tem observation in rule spherical shape；Taxol and resveratrol are present in drug-carrying nanometer particle in the form of unformed；It is logical
Cross the Time Dependent stability under the conditions of Malvern ParticleSizer measures 4 DEG C and the stability in DMEM；Taxol/white is obtained
The release profiles of veratryl alcohol albumin nano granular；Taxol/resveratrol albumin nanoparticle is demonstrated in body by MTT experiment
The advantage of outer anticancer activity.
Only the present invention will be further described for the above various embodiments, is not intended to limit the invention patent, all is this hair
Bright equivalence enforcement, is intended to be limited solely by within the scope of the claims of the invention patent.
Thank state natural sciences fund (21473085), Shandong Province's emphasis research and development planning item (2015GSF118160),
Shandong Province's Natural Science Fund In The Light (ZR2017BH065), institution of higher education, Shandong Province plan of science and technology (J17KA234) are to the money of this project
It helps.
Claims (8)
1. a kind of double medicine albumin nano granulars, which is characterized in that it includes albumin, hydrophobic drug taxol and white Chenopodiaceae that it, which is formed,
Reed alcohol.
2. double medicine albumin nano granulars as described in claim 1, which is characterized in that the albumin is bovine serum albumin
It is white.
3. double medicine albumin nano granulars as described in claim 1, which is characterized in that the molar ratio of albumin and hydrophobic drug
For 1:9.
4. double medicine albumin nano granulars as described in claim 1, which is characterized in that its partial size is 100-200 nm.
5. double medicine albumin nano granulars as described in claim 1, it is characterised in that: in the nanoparticle, taxol, white black false hellebore
The drugloading rate of alcohol is between 1-5%.
6. double medicine albumin nano granulars as described in claim 1, it is characterised in that: in the nanoparticle, taxol, white black false hellebore
The encapsulation rate of alcohol is 99% or more.
7. double medicine albumin nano granulars as described in claim 1, it is characterised in that: the nanoparticle has reversed taxol resistance
The drug resistance of cell.
8. double medicine albumin nano granulars as claimed in claim 1, which is characterized in that it is heavy that preparation method combines anti-solvent
Shallow lake method and high pressure homogenization method, specifically includes the following steps:
A. albumin is dissolved in water three times, is sufficiently dissolved；
B. two kinds of hydrophobic drugs are dissolved in organic solvent；
C. the organic solvent of step b is added in the albumin aqueous solution of step a, stirs 10 min；
D. the solution vacuum distillation of step c is removed into organic solvent；
E. the solution progress of step d is high-pressure homogeneous, size controlling is obtained in double medicine albumin nano granulars of 100-200 nm.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910158514.2A CN109806241A (en) | 2019-03-04 | 2019-03-04 | A kind of double medicine albumin nano granulars and preparation process |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910158514.2A CN109806241A (en) | 2019-03-04 | 2019-03-04 | A kind of double medicine albumin nano granulars and preparation process |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109806241A true CN109806241A (en) | 2019-05-28 |
Family
ID=66608150
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910158514.2A Pending CN109806241A (en) | 2019-03-04 | 2019-03-04 | A kind of double medicine albumin nano granulars and preparation process |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109806241A (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111166723A (en) * | 2019-12-30 | 2020-05-19 | 广西师范大学 | Human serum albumin-ginsenoside-paclitaxel nanoparticles and preparation and application thereof |
| CN111297807A (en) * | 2020-02-13 | 2020-06-19 | 东北农业大学 | Method for preparing bifunctional genistein-high polymer nano complex by ion crosslinking method and application |
| CN111939151A (en) * | 2020-07-04 | 2020-11-17 | 浙江工业大学 | Composite adriamycin albumin nanoparticle and preparation method and application thereof |
| CN112336704A (en) * | 2019-08-06 | 2021-02-09 | 永胜药品工业股份有限公司 | Pharmaceutical composition for treating drug-resistant cancer |
| CN113797340A (en) * | 2020-06-12 | 2021-12-17 | 华东师范大学 | Anti-tumor double-medicine nano preparation and preparation method and application thereof |
| CN113908276A (en) * | 2021-10-22 | 2022-01-11 | 复旦大学附属金山医院(上海市金山区核化伤害应急救治中心、上海市金山区眼病防治所) | Light-controlled drug release nano particle and preparation method and application thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102641246A (en) * | 2012-03-19 | 2012-08-22 | 南京维赛医药科技有限公司 | Anti-tumor double-drug nano drug carrying microsphere and preparation method thereof |
| WO2013172999A1 (en) * | 2012-05-16 | 2013-11-21 | Mewa Singh | Pharmaceutical compositions for the delivery of substantially water-insoluble drugs |
| CN106333941A (en) * | 2016-10-24 | 2017-01-18 | 聊城大学 | Process for preparing paclitaxel albumin compound |
| CN107802614A (en) * | 2017-12-11 | 2018-03-16 | 中国药科大学 | A kind of oral albumin nano granular in intestines and stomach with high stability |
| CN109364029A (en) * | 2018-12-04 | 2019-02-22 | 临沂大学 | A kind of resveratrol microballoon and preparation method thereof |
-
2019
- 2019-03-04 CN CN201910158514.2A patent/CN109806241A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102641246A (en) * | 2012-03-19 | 2012-08-22 | 南京维赛医药科技有限公司 | Anti-tumor double-drug nano drug carrying microsphere and preparation method thereof |
| WO2013172999A1 (en) * | 2012-05-16 | 2013-11-21 | Mewa Singh | Pharmaceutical compositions for the delivery of substantially water-insoluble drugs |
| CN106333941A (en) * | 2016-10-24 | 2017-01-18 | 聊城大学 | Process for preparing paclitaxel albumin compound |
| CN107802614A (en) * | 2017-12-11 | 2018-03-16 | 中国药科大学 | A kind of oral albumin nano granular in intestines and stomach with high stability |
| CN109364029A (en) * | 2018-12-04 | 2019-02-22 | 临沂大学 | A kind of resveratrol microballoon and preparation method thereof |
Non-Patent Citations (5)
| Title |
|---|
| JIE MENG ET AL.: "Combination Therapy using Co-encapsulated Resveratrol and Paclitaxel in Liposomes for Drug Resistance Reversal in Breast Cancer Cells in vivo", 《SCIENTIFIC REPORTS》 * |
| MENGYING HU ET AL.: "Polymer micelle-based combination therapy of paclitaxel and resveratrol with enhanced and selective antitumor activity", 《RSC ADVANCES》 * |
| 吴异兰等: "白藜芦醇对肺癌紫杉醇耐药细胞的增殖抑制作用及其机制", 《癌变·畸变·突变》 * |
| 潘洪明等: "紫杉醇与白藜芦醇联合应用对人胃癌MGC803细胞作用的研究", 《中华中医药杂志》 * |
| 蔡畅等: "不同药载比的紫杉醇白蛋白纳米粒的制备及释药性能研究", 《聊城大学学报（自然科学版）》 * |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112336704A (en) * | 2019-08-06 | 2021-02-09 | 永胜药品工业股份有限公司 | Pharmaceutical composition for treating drug-resistant cancer |
| CN111166723A (en) * | 2019-12-30 | 2020-05-19 | 广西师范大学 | Human serum albumin-ginsenoside-paclitaxel nanoparticles and preparation and application thereof |
| CN111166723B (en) * | 2019-12-30 | 2021-09-10 | 广西师范大学 | Human serum albumin-ginsenoside-paclitaxel nanoparticles and preparation and application thereof |
| CN111297807A (en) * | 2020-02-13 | 2020-06-19 | 东北农业大学 | Method for preparing bifunctional genistein-high polymer nano complex by ion crosslinking method and application |
| CN111297807B (en) * | 2020-02-13 | 2021-09-21 | 东北农业大学 | Method for preparing bifunctional genistein-high polymer nano complex by ion crosslinking method and application |
| CN113797340A (en) * | 2020-06-12 | 2021-12-17 | 华东师范大学 | Anti-tumor double-medicine nano preparation and preparation method and application thereof |
| CN111939151A (en) * | 2020-07-04 | 2020-11-17 | 浙江工业大学 | Composite adriamycin albumin nanoparticle and preparation method and application thereof |
| CN113908276A (en) * | 2021-10-22 | 2022-01-11 | 复旦大学附属金山医院(上海市金山区核化伤害应急救治中心、上海市金山区眼病防治所) | Light-controlled drug release nano particle and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109806241A (en) | A kind of double medicine albumin nano granulars and preparation process | |
| Yu et al. | ROS-responsive nano-drug delivery system combining mitochondria-targeting ceria nanoparticles with atorvastatin for acute kidney injury | |
| Ganeshkumar et al. | Green synthesis of pullulan stabilized gold nanoparticles for cancer targeted drug delivery | |
| Majedi et al. | On‐chip fabrication of paclitaxel‐loaded chitosan nanoparticles for cancer therapeutics | |
| Song et al. | Paclitaxel-loaded redox-sensitive nanoparticles based on hyaluronic acid-vitamin E succinate conjugates for improved lung cancer treatment | |
| Punfa et al. | Enhancement of cellular uptake and cytotoxicity of curcumin-loaded PLGA nanoparticles by conjugation with anti-P-glycoprotein in drug resistance cancer cells | |
| Tummala et al. | Improved anti-tumor activity of oxaliplatin by encapsulating in anti-DR5 targeted gold nanoparticles | |
| Fathi et al. | Folate-conjugated thermosensitive O-maleoyl modified chitosan micellar nanoparticles for targeted delivery of erlotinib | |
| Liao et al. | Novel walnut peptide–selenium hybrids with enhanced anticancer synergism: Facile synthesis and mechanistic investigation of anticancer activity | |
| Zhong et al. | A self-assembling nanomedicine of conjugated linoleic acid-paclitaxel conjugate (CLA-PTX) with higher drug loading and carrier-free characteristic | |
| Sun et al. | The cost-effective preparation of green fluorescent carbon dots for bioimaging and enhanced intracellular drug delivery | |
| Bhushan et al. | Bionanotherapeutics: niclosamide encapsulated albumin nanoparticles as a novel drug delivery system for cancer therapy | |
| Banerjee et al. | Integrating the drug, disulfiram into the vitamin E-TPGS-modified PEGylated nanostructured lipid carriers to synergize its repurposing for anti-cancer therapy of solid tumors | |
| Muddineti et al. | Curcumin-loaded chitosan–cholesterol micelles: evaluation in monolayers and 3D cancer spheroid model | |
| Liu et al. | Delivery of apigenin-loaded magnetic Fe2O3/Fe3O4@ mSiO2 nanocomposites to A549 cells and their antitumor mechanism | |
| Javan et al. | Development of a magnetic nanostructure for co-delivery of metformin and silibinin on growth of lung cancer cells: Possible action through leptin gene and its receptor regulation | |
| Li et al. | Synergistically fabricated polymeric nanoparticles featuring dual drug delivery system to enhance the nursing care of cervical cancer | |
| Taheri-Ledari et al. | A magnetic antibody-conjugated nano-system for selective delivery of Ca (OH) 2 and taxotere in ovarian cancer cells | |
| Chen et al. | Curcumin/sunitinib co-loaded BSA-stabilized SPIOs for synergistic combination therapy for breast cancer | |
| Kumar et al. | Ultrafast synthesis of stabilized gold nanoparticles using aqueous fruit extract of Limonia acidissima L. and conjugated epirubicin: targeted drug delivery for treatment of breast cancer | |
| Chaturvedi et al. | Rapid eco-friendly synthesis, characterization, and cytotoxic study of trimetallic stable nanomedicine: A potential material for biomedical applications | |
| Yang et al. | Preparation and characterization of tadpole-and sphere-shaped hemin nanoparticles for enhanced solubility | |
| Shahlaei et al. | Increasing the effectiveness of oxaliplatin using colloidal immunoglobulin G nanoparticles: Synthesis, cytotoxicity, interaction, and release studies | |
| Firouzi-Amandi et al. | Development, characterization, and in vitro evaluation of cytotoxic activity of Rutin loaded PCL-PEG nanoparticles against Skov3 ovarian cancer cell | |
| Chen et al. | Designing biocompatible protein nanoparticles for improving the cellular uptake and antioxidation activity of tetrahydrocurcumin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190528 |
|
| RJ01 | Rejection of invention patent application after publication |